Injectables remain the largest segment of the drug delivery market, but the technology has evolved far beyond the simple syringe. In 2025, the autoinjector has become the gold standard for the delivery of monoclonal antibodies (mAbs). These devices are designed for one-handed operation and feature "hidden needles" to reduce phobia, ensuring that patients receive the exact dose required without the risk of "needle-stick" injuries.

Data from the Drug Delivery Devices Market analysis indicates that the autoinjector segment holds over 35% of the injectable market share. A major trend in 2025 is the development of "high-volume" injectors. As biologics become more concentrated, they also become more viscous, requiring more force to inject. New devices utilize specialized springs or motorized drives to deliver up to 5ml of medication over several seconds, allowing for subcutaneous delivery of drugs that previously required a two-hour hospital IV infusion.

The move toward "Prefilled Syringes" (PFS) also continues to gain momentum. PFS eliminate the need for the patient to "draw up" the medication from a vial, reducing the risk of dosing errors and contamination. In 2025, the integration of "Safety Syringes"—which feature retractable needles or automatic shields—is becoming a regulatory mandate in many developed markets to protect healthcare workers and caregivers. This focus on "Safety and Simplicity" is the primary driver of market value in the injectable space.